UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015904
Receipt number R000018511
Scientific Title A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS
Date of disclosure of the study information 2014/12/10
Last modified on 2020/06/16 10:50:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS

Acronym

A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS

Scientific Title

A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS

Scientific Title:Acronym

A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS

Region

Japan


Condition

Condition

Early Onset Pediatric Scoliosis

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To Evaluate clinical safety and probable benefit of the investigational device system, MDT-4113, when the system is used for patients with severe, progressive, and life-threatening Early Onset Scoliosis associated with thoracic insufficiency syndrome

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Success is defined as a postoperative 24 months major curve Cobb angle less than or equal to 50+/-5 degrees or an improvement of at least 50% compared to preoperative. (+/-5 is error of measurement)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Implantation of MDT-4113
From operation for MDT-4113 implantation to postoperative 24 months or final fusion operation

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

10 years-old >

Gender

Male and Female

Key inclusion criteria

1. Diagnosed to severe, progressive, life-threatening Early Onset Scoliosis including congenital scoliosis, juvenile scoliosis, neuromuscular scoliosis and syndromic scoliosis
2. Preoperative major curve Cobb Angle >50 +/-5 degrees (+/-5 degrees is error of measurement)
3. Spinal Curve length over at least 6 segments of the spine
4. Is less than 10 years of age at the time of the index surgery
5. His/her parent or legal guardian has signed the Informed Consent form

Key exclusion criteria

1. Has active infection and/or has significant infectious risk
2. Is diagnosed to allergy or hypersensitivity to metal or is suspect to metal allergy/hypersensitivity
3. General anesthesia is NOT appropriate
4. Operated on spinal fusion with implant(s)
5. Had participated other clinical trial during the last 3 months
6. Has convulsion (If an investigator decides that a patient is not appropriate to enter this study)
7. Has untreated syringomyelia, spinal deformity or spinal cord tumor
8. Reaches skeletal maturity
9. Has inadequate tissue coverage over the operative site
10. Has hypophrenia (If an investigator decides that a patient is not appropriate to enter this study.)
11. Has rib fusion
12. His/her parent or legal guardian has not signed the Informed Consent form

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Asami
Middle name
Last name Taguchi

Organization

Medtronic Sofamor Danek, Co., Ltd.

Division name

Regulatory and Clinical Affairs

Zip code

108-0075

Address

Shinagawa Season Terrace 1-2-70 Konan, Minato-ku, Tokyo

TEL

03-6776-0018

Email

asami.taguchi@medtronic.com


Public contact

Name of contact person

1st name Asami
Middle name
Last name Taguchi

Organization

Medtronic Sofamor Danek, Co., Ltd.

Division name

Regulatory and Clinical Affairs

Zip code

108-0075

Address

Shinagawa Season Terrace 1-2-70 Konan, Minato-ku, Tokyo

TEL

03-6776-0352

Homepage URL


Email

asami.taguchi@medtronic.com


Sponsor or person

Institute

Medtronic Sofamor Danek, Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Medtronic Sofamor Danek, Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medtronic Sofamor Danek,Co.,Ltd.

Address

Shinagawa Season Terrace, 1-2-70, Konan, Minato-ku, Tokyo

Tel

03-6776-0018

Email

asami.taguchi@medtronic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2014 Year 03 Month 31 Day

Date of IRB

2014 Year 07 Month 15 Day

Anticipated trial start date

2014 Year 09 Month 05 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry

2022 Year 12 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 10 Day

Last modified on

2020 Year 06 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018511


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name